Effects of Isotretinoin on CYP2D6 Activity

Status Completed

Clinical Trial Summary

Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.

Clinical Trial Description

In this aim, we will conduct a drug-drug interaction study evaluating the effects of 13-cis-retinoic acid on non-induced CYP2D6 activity in adolescent patients. Secondary analysis will evaluate the relationship between retinoid concentrations and CYP2D6 activity in these special populations ;

Study Design

Related Conditions & MeSH terms

CYP2D6 Polymorphism

Clinical Trial Details

NCT number	NCT03076021
Study type	Interventional
Source	University of Washington
Contact
Status	Completed
Phase	Phase 4
Start date	July 26, 2016
Completion date	November 27, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04228315` - Biomarkers of P. Vivax Relapse	N/A
Completed	`NCT01075802` - Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms	N/A
Completed	`NCT03117660` - Effects of Retinoids on CYP2D6 Activity During Pregnancy	Phase 1
Completed	`NCT03411759` - Cytochrome P450's Pharmacogenomics in Chronic Pain Patients
Completed	`NCT02428660` - Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM	N/A
Enrolling by invitation	`NCT03137368` - A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）	Phase 3
Completed	`NCT02664350` - Precision Medicine Guided Treatment for Cancer Pain	N/A